Paul Emery - Concepedia

Author

Paul Emery

Also Known As

A. S. Russell, Ann W. Morgan, B. Krummel-Lorenz, Bertrand Wechsler, C. Owen, C. T. Pease, Christopher Edwards, Colin Pease, Costantino Pitzalis, D. G. Hutchinson

1.6K

Publications

127K

Citations

158

H-Index

191

Concepts

All Affiliations

University of Leeds NIHR Leeds Musculoskeletal Biomedical Research Unit Leeds Teaching Hospitals NHS Trust Chapel Allerton Hospital Leiden University Medical Center

About

Paul Emery is an author at University of Leeds specializing in medicine, rheumatoid arthritis, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	105	13.8K
2	Health Sciences	19	21	2.4K
3	Engineering	3	3	150
4	Public Health	3	3	100
5	Social Sciences	1	1	31

Paul Emery

575

Publications

98.7K

Citations

143

H-Index

Page 1

	Year	Citations
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative Daniel Aletaha, Tuhina Neogi, Alan J. Silman, Arthritis & Rheumatism	2010	9.3K
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair, New England Journal of Medicine	2000	3K
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Annals of the Rheumatic Diseases	2020	2.6K
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis Jonathan Edwards, L Szczepański, Jacek Szechiński, New England Journal of Medicine	2004	2.6K
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld, The Lancet InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryAutoimmune Disease	1999	2.3K
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld, Annals of the Rheumatic Diseases	2013	1.8K
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks Stanley Cohen, Paul Emery, Maria Greenwald, Arthritis & Rheumatism	2006	1.6K
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial E. William St. Clair, Désirée van der Heijde, Josef S Smolen, Arthritis & Rheumatism	2004	1.2K
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Paul Emery, Edward Keystone, Hans‐Peter Tony, Annals of the Rheumatic Diseases	2008	1.1K
Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig Joel M. Kremer, René Westhovens, Marc Léon, New England Journal of Medicine	2003	1.1K

Page 1